JoVE - Journal of Visualized Experiments
JoVE Visualize
Research Domains
View All

Contact Us

Therapeutic approaches for pulmonary artery pseudoaneurysms and analysis of outcomes

  • 1Department of Radiology, Dokuz Eylul University Medical School Hospital, Izmir, Türkiye.
  • 2Department of Radiology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. sorock71@snu.ac.kr.
  • 3Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea. sorock71@snu.ac.kr.
  • 4Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea. sorock71@snu.ac.kr.
  • 5Department of Radiology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
  • 6Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • 7Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.
+

|

June 14, 2025

Abstract

OBJECTIVES

To evaluate the therapeutic approaches for pulmonary artery pseudoaneurysms (PAPs) with various etiologies and types, and outcomes.

MATERIALS AND METHODS

Between March 2010 and March 2024, 30 PAPs were identified in 29 patients. We analyzed the medical records of 29 PAPs in 28 patients whose etiologies were confirmed. Patient characteristics, underlying lung abnormalities, PAPs' characteristics, therapeutic approaches, and outcomes were evaluated.

RESULTS

Twenty-nine PAPs were treated in 28 patients (mean age 59 years ± 12.4; 25 males). The etiologies of PAPs were pulmonary tuberculosis (n = 22), necrotizing pneumonia (n = 6), and iatrogenic (n = 1). In one tuberculosis patient, two PAPs occurred at different times. Hemoptysis volume varied according to etiology, with no hemoptysis in iatrogenic PAP. In 21 PAPs, pulmonary artery embolization (PAE) (n = 15), embolization via systemic-to-pulmonary shunt or bronchial/non-bronchial systemic artery embolization (BAE/SAE) (n = 5), and medical treatment (n = 1) were performed after pulmonary arteriography. For eight PAPs, embolization via systemic-to-pulmonary shunt or BAE/SAE (n = 7), and medical treatment (n = 1) were performed without additional pulmonary arteriography. Two patients underwent medical treatment because they had small (< 5 mm) or isolated PAP from the pulmonary artery. In 23 patients (24 PAPs), PAPs regressed or hemoptysis ceased. Two patients underwent surgery during follow-up. Three patients died from sepsis or massive hemoptysis. There were no complications related to the procedure.

CONCLUSION

PAE is an effective treatment for PAPs, but empirical embolization via systemic-to-pulmonary artery shunt can be an effective alternative treatment for PAPs not detected on pulmonary angiography. In addition, medical treatment can be considered in small or isolated PAPs.

KEY POINTS

Question Due to the rarity of pulmonary pseudoaneurysms, mostly seen in severe chronic infectious pulmonary disease such as tuberculosis, percutaneous treatment has not yet been standardized. Findings Transcatheter embolization via the pulmonary artery itself and often via systemic artery, in particular bronchial-to-pulmonary-artery shunts, is an effective treatment of those pseudoaneurysms. Clinical relevance Life-threatening pulmonary hemorrhage can be treated using superselective embolization which requires an individual treatment plan based on the etiology of hemorrhage, the clinical status of the patient, and the vascularization of the pseudoaneurysms as shown by CT and angiography.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers 01:26

149

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists 01:18

145

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists 01:23

162

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure 01:16

189

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...